{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:01:43Z","timestamp":1781719303568,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1013872","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000}}],"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["BC240538"],"award-info":[{"award-number":["BC240538"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>\n                    Antibody-drug conjugates (ADCs) have had remarkable clinical success in recent years with multiple new approvals. However, for some ADCs, the response rates don\u2019t closely correlate with clinical target expression. One particular ADC targeting HER2, trastuzumab deruxtecan or T-DXd, is notable due to its success at expression levels ranging from high to low and ultralow. This raises the question of the relative contributions of target-independent mechanisms on ADC efficacy in the clinic, and several such mechanisms have been proposed. However,\n                    <jats:italic>in vitro<\/jats:italic>\n                    and preclinical data have different doses and exposures, making it challenging to quantitatively extrapolate preclinical data to the clinic. In this work, we use our computational hybrid agent-based model,\n                    <jats:italic>SimADC,<\/jats:italic>\n                    to simulate target-dependent and -independent mechanisms, scaling from mice to humans. We first demonstrate that CD8\u2009+\u2009T cells can significantly contribute to tumor regression, especially when the ADC further activates the immune cells. Next, we test target-independent payload-driven mechanisms including: 1) Fc-mediated internalization of ADC by intratumoral macrophages and payload release to neighboring cancer cells, 2) free payload circulating in the blood and re-entering the tumor, and 3) extracellular linker cleavage and payload release due to an abundance of proteases in the tumor. We find that free payload in the blood and extracellular linker cleavage had low and moderate impacts, respectively, while macrophage uptake and payload release resulted in high levels of efficacy. This is due to the macrophages\u2019 ability to sustain free payload in the tumor. Moderate and high HER2 expression were more efficacious than target-independent mechanisms. Overall, our simulations demonstrate that moderate to high HER2 expression, immune activation, or macrophage uptake and payload release are sufficient for T-DXd tumor regression. Additionally,\n                    <jats:italic>SimADC<\/jats:italic>\n                    provides a robust framework for modeling both target-dependent and target-independent mechanisms for any ADC, providing the opportunity to engineer more effective therapeutic agents.\n                  <\/jats:p>","DOI":"10.1371\/journal.pcbi.1013872","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:42:26Z","timestamp":1779817346000},"page":"e1013872","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agent-based modeling demonstrates how target-independent processes supplement killing by antibody-drug conjugates in cancer therapy"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-335X","authenticated-orcid":true,"given":"Melissa C.","family":"Calopiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Linderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-2080","authenticated-orcid":true,"given":"Greg M.","family":"Thurber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"23","key":"pcbi.1013872.ref001","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"KN Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"pcbi.1013872.ref002","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s13046-020-01797-3","article-title":"Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study","volume":"39","author":"G Bon","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"pcbi.1013872.ref003","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"F Mosele","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"pcbi.1013872.ref004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13550-024-01079-5","article-title":"Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET","volume":"14","author":"JE Wijngaarden","year":"2024","journal-title":"EJNMMI Res"},{"key":"pcbi.1013872.ref005","doi-asserted-by":"crossref","first-page":"836925","DOI":"10.3389\/fphar.2022.836925","article-title":"Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics","volume":"13","author":"S Dong","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"pcbi.1013872.ref006","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","article-title":"Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates","volume":"21","author":"E Khera","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"pcbi.1013872.ref007","article-title":"Optimizing solid tumor treatment with antibody\u2013drug conjugates using agent-based modeling: considering the role of a carrier dose and payload class","author":"MC Calopiz","year":"2024","journal-title":"Pharm Res"},{"issue":"10","key":"pcbi.1013872.ref008","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"J Rios-Doria","year":"2017","journal-title":"Cancer Res"},{"issue":"7","key":"pcbi.1013872.ref009","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody\u2013drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"TN Iwata","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"pcbi.1013872.ref010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","article-title":"Tumor-associated macrophages can contribute to antitumor activity through Fc\u03b3R-mediated processing of antibody-drug conjugates","volume":"16","author":"F Li","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"pcbi.1013872.ref011","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"L-C Tsao","year":"2025","journal-title":"Nat Commun"},{"issue":"7","key":"pcbi.1013872.ref012","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/ijc.30569","article-title":"Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix","volume":"140","author":"R G\u00e9bleux","year":"2017","journal-title":"Int J Cancer"},{"key":"pcbi.1013872.ref013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddtec.2020.07.002","article-title":"Antibody-drug conjugates as targeted therapies: are we there yet? A critical review of the current clinical landscape","volume":"37","author":"E Tarcsa","year":"2020","journal-title":"Drug Discov Today Technol"},{"issue":"22","key":"pcbi.1013872.ref014","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"B Rubahamya","year":"2024","journal-title":"Sci Adv"},{"issue":"5","key":"pcbi.1013872.ref015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/1087057114521867","article-title":"A new bliss independence model to analyze drug combination data","volume":"19","author":"W Zhao","year":"2014","journal-title":"J Biomol Screen"},{"issue":"315","key":"pcbi.1013872.ref016","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac4925","article-title":"Trastuzumab emtansine (T-DM1) renders HER2 breast cancer highly susceptible to CTLA-4\/PD-1 blockade","volume":"7","author":"P M\u00fcller","year":"2015","journal-title":"Sci Transl Med"},{"issue":"4","key":"pcbi.1013872.ref017","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1083\/jcb.98.4.1170","article-title":"Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes","volume":"98","author":"I Mellman","year":"1984","journal-title":"J Cell Biol"},{"issue":"16","key":"pcbi.1013872.ref018","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"P Bruhns","year":"2009","journal-title":"Blood"},{"issue":"4","key":"pcbi.1013872.ref019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clml.2012.01.012","article-title":"Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms","volume":"12","author":"JR Fromm","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"pcbi.1013872.ref020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/psp4.13133","article-title":"Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression","volume":"13","author":"C Vasalou","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"20","key":"pcbi.1013872.ref021","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Y Ogitani","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"pcbi.1013872.ref022","first-page":"2527","article-title":"A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies","volume":"9","author":"MA Garrison","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"pcbi.1013872.ref023","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1002\/jps.24086","article-title":"Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors","volume":"103","author":"S Bhatnagar","year":"2014","journal-title":"J Pharm Sci"},{"issue":"9","key":"pcbi.1013872.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024696","article-title":"A systems approach for tumor pharmacokinetics","volume":"6","author":"GM Thurber","year":"2011","journal-title":"PLoS One"},{"issue":"23","key":"pcbi.1013872.ref025","first-page":"6449","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"P Vaupel","year":"1989","journal-title":"Cancer Res"},{"issue":"10","key":"pcbi.1013872.ref026","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1080\/00498254.2020.1755909","article-title":"Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice","volume":"50","author":"H Okamoto","year":"2020","journal-title":"Xenobiotica"},{"issue":"3","key":"pcbi.1013872.ref027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002800050807","article-title":"Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice","volume":"42","author":"E Kumazawa","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"pcbi.1013872.ref028","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1039\/C7ME00093F","article-title":"Computational transport analysis of antibody-drug conjugate bystander effects and payload tumoral distribution: implications for therapy","volume":"3","author":"E Khera","year":"2018","journal-title":"Molecular Systems Design & Engineering"},{"issue":"2","key":"pcbi.1013872.ref029","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1208\/s12248-019-0387-x","article-title":"Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation","volume":"22","author":"AP Singh","year":"2020","journal-title":"AAPS J"},{"issue":"16","key":"pcbi.1013872.ref030","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1158\/1078-0432.CCR-06-0544","article-title":"Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine","volume":"12","author":"K Kimura","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"pcbi.1013872.ref031","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/tbcr-25-8","article-title":"Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses","volume":"6","author":"S Wu","year":"2025","journal-title":"Transl Breast Cancer Res"},{"issue":"1","key":"pcbi.1013872.ref032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"S Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"pcbi.1013872.ref033","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3390\/cancers14102525","article-title":"Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response","volume":"14","author":"BL Rapoport","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"pcbi.1013872.ref034","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment","volume":"25","author":"A Zippelius","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"pcbi.1013872.ref035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000416","article-title":"Characterization of human cancer xenografts in humanized mice","volume":"8","author":"J Rios-Doria","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"pcbi.1013872.ref036","article-title":"Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer","volume":"43","author":"D Ma","year":"2025","journal-title":"Cancer Cell"},{"key":"pcbi.1013872.ref037","article-title":"432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician\u2019s choice in HER2-low, hormone receptor\u2013positive metastatic breast cancer in DESTINY-Breast04","volume":"35","author":"NT Ueno","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"pcbi.1013872.ref038","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"D Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"pcbi.1013872.ref039","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"J Wu","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"pcbi.1013872.ref040","first-page":"1","article-title":"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan","volume":"53","author":"CF Verschraegen","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"pcbi.1013872.ref041","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cncr.11557","article-title":"A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma","volume":"98","author":"FJ Esteva","year":"2003","journal-title":"Cancer"},{"issue":"7","key":"pcbi.1013872.ref042","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/bcp.16057","article-title":"Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates","volume":"90","author":"H-P Chang","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pcbi.1013872.ref043","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41698-026-01365-6","article-title":"Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer","volume":"10","author":"P Tarantino","year":"2026","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"pcbi.1013872.ref044","doi-asserted-by":"crossref","first-page":"12129","DOI":"10.1038\/s41598-024-61957-9","article-title":"HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer","volume":"14","author":"A Kapil","year":"2024","journal-title":"Scientific Reports"},{"issue":"5","key":"pcbi.1013872.ref045","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ajpath.2013.07.015","article-title":"Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients","volume":"183","author":"MD Onsum","year":"2013","journal-title":"Am J Pathol"},{"issue":"10","key":"pcbi.1013872.ref046","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41374-022-00804-9","article-title":"Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer","volume":"102","author":"M Moutafi","year":"2022","journal-title":"Lab Invest"},{"issue":"10","key":"pcbi.1013872.ref047","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2967\/jnumed.124.267636","article-title":"Whole-body HER2 heterogeneity identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer","volume":"65","author":"B Eisses","year":"2024","journal-title":"J Nucl Med"},{"issue":"12","key":"pcbi.1013872.ref048","article-title":"Multi-scale modeling of macrophage\u2014T cell interactions within the tumor microenvironment. Miller-Jensen K, editor","volume":"16","author":"CG Cess","year":"2020","journal-title":"PLOS Comput Biol"},{"issue":"1","key":"pcbi.1013872.ref049","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","article-title":"Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release","volume":"22","author":"A Kopp","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"pcbi.1013872.ref050","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-12-3349","article-title":"HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab","volume":"73","author":"S Ithimakin","year":"2013","journal-title":"Cancer Res"},{"issue":"6","key":"pcbi.1013872.ref051","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1158\/1078-0432.CCR-08-1327","article-title":"Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab","volume":"15","author":"A Magnifico","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"pcbi.1013872.ref052","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1208\/s12248-019-0391-1","article-title":"An agent-based systems pharmacology model of the antibody-drug conjugate kadcyla to predict efficacy of different dosing regimens","volume":"22","author":"B Menezes","year":"2020","journal-title":"AAPS J"},{"issue":"1","key":"pcbi.1013872.ref053","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/dmd.121.000503","article-title":"Simulating the selection of resistant cells with bystander killing and antibody coadministration in heterogeneous human epidermal growth factor receptor 2-positive tumors","volume":"50","author":"B Menezes","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"pcbi.1013872.ref054","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"S Marino","year":"2008","journal-title":"J Theor Biol"},{"key":"pcbi.1013872.ref055","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"FR Balkwill","year":"2012","journal-title":"J Cell Sci"},{"issue":"1","key":"pcbi.1013872.ref056","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1186\/s12885-021-08974-3","article-title":"Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response","volume":"21","author":"Y Sato","year":"2021","journal-title":"BMC Cancer"},{"key":"pcbi.1013872.ref057","volume-title":"Engineering protein-drug conjugates for solid tumor immunotherapy","author":"I Nessler","year":"2022"},{"issue":"6","key":"pcbi.1013872.ref058","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","article-title":"Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK\/PD model: a case study with brentuximab-vedotin","volume":"39","author":"DK Shah","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"pcbi.1013872.ref059","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"T Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"pcbi.1013872.ref060","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.xphs.2019.01.034","article-title":"A \u201cDual\u201d cell-level systems PK-PD model to characterize the bystander effect of ADC","volume":"108","author":"AP Singh","year":"2019","journal-title":"J Pharm Sci"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1013872","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:48:29Z","timestamp":1781718509000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013872"}},"subtitle":[],"editor":[{"given":"Melissa L.","family":"Kemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1013872","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}